Evidence map›Paper›PMID 41837632›Full record

ReviewmSphere2026

Planning for the future of the American Society for Microbiology's Health Unit by the Council on Microbial Sciences.

Austin J Fox, Andrea M Prinzi, Nancy W Wamburu, Nicholas M Moore, Michael M Lieberman, Kileen Shier, Nancy L Haigwood

Abstract readReview
In one paragraph

Review in mSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Austin J FoxWisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA.
Andrea M PrinziUS Medical Affairs, bioMérieux, Salt Lake City, Utah, USA.ORCID 0000-0003-2949-5484
Nancy W WamburuAmerican Society for Microbiology, Washington, DC, USA.
Nicholas M MooreDivision of Clinical Microbiology, College of Health Sciences, Rush University, Chicago, Illinois, USA.ORCID 0000-0002-9734-8905
Michael M LiebermanUniversity of Hawaii, John A Burns School of Medicine, Honolulu, Hawaii, USA.
Kileen ShierQuest Diagnostics, Chantilly, Virginia, USA.
Nancy L HaigwoodOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-1477-9575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In February and March 2025, the American Society for Microbiology (ASM)'s Council on Microbial Sciences (COMS) hosted a series of virtual retreats to integrate the communities of Clinical Infections and Vaccines (CIV) and Clinical and Public Health Microbiology (CPHM) under the umbrella of the new scientific unit ASM Health. Representatives from these two communities invited experts and ASM members to reflect on the current state of the science, identify challenges hindering scientific advancements, and propose recommendations for overcoming these challenges. Sessions focused on progress in (i) vaccines, therapeutics, diagnostics, and global pathogen surveillance; (ii) improving data integration and cross-agency sharing; (iii) supporting the microbial health workforce; and (iv) gaining public support and confidence in microbiology. Four major recommendations emerged for ASM Health. First, increased support for microbiological science is crucial to ensure the advancement of vaccines, therapeutics, diagnostics, and global pathogen surveillance to mitigate infectious disease threats. Second, enhancement of data integration and sharing in real-time via information systems will facilitate a deeper understanding of disease epidemiology. Third, modern approaches to recruitment, career path, and profession awareness, and dynamic training programs are necessary to achieve microbial workforce balance. Fourth, microbiologists will benefit from outreach training and resources designed to restore public trust in an environment that questions science and evidence-based approaches. ASM is uniquely positioned to take a pivotal leadership role to develop these concepts into specific programs, as well as to enhance partnerships across the spectrum to innovate in funding, both for scientific research and public health.

Indexed as

MicrobiologyPublic HealthSocieties, ScientificHumansUnited StatesVaccinesVaccinesclinical microbiologyclinical therapeuticsdata integrationdiagnosticsinfectious diseaseoutreachpublic healthsurveillance studiesvaccinesveterinary microbiology

Identifiers

PMID41837632
PMCPMC13123707

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.